Navigation Links
Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock
Date:10/16/2009

ALPHARETTA, Ga., Oct. 16 /PRNewswire/ -- Cellu Tissue Holdings, Inc. ("Cellu Tissue") today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of shares of its common stock. The offered shares will include shares to be sold by Cellu Tissue and shares to be sold by stockholders of the company. The total number of shares to be offered, the allocation of shares to be sold as between Cellu Tissue and stockholders and the price range for the offering have not yet been determined. Cellu Tissue intends to use the net proceeds it receives from the offering to pay down certain indebtedness, including, but not limited to, potentially redeeming or repurchasing a portion of its outstanding senior secured notes, and the remaining net proceeds, if any, for general corporate purposes. Cellu Tissue will not receive any of the proceeds from the sale of shares by the selling stockholders.

Cellu Tissue intends to apply to list the common stock on the New York Stock Exchange under the ticker symbol "CLU."

Goldman, Sachs & Co. and J.P. Morgan Securities Inc. will act as joint book running managers for the offering. The offering will only be made by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained by contacting either Goldman, Sachs & Co., at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, by telephone at 1-866-471-2526 or by emailing Prospectus-ny@ny.email.gs.com, or J.P. Morgan Securities Inc. at National Statement Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, New York, NY, 11245, or by telephone at 718-242-8002.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which the offer, solicitation or sale of securities would be unlawful prior to their registration and qualification under the securities laws of any such state or jurisdiction.

SOURCE Cellu Tissue Holdings, Inc.


'/>"/>
SOURCE Cellu Tissue Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
3. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
6. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
7. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
8. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
9. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
10. Cellular construction methods emulated
11. GreenField Ethanol and Enerkem Announce Plans to Make Cellulosic Ethanol a Commercial Reality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
Breaking Biology Technology:
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):